TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE
COMB157G3301
Phase 3 small_molecule active
Quick answer
TERIFLUNOMIDE, INTERFERON BETA-1A, DIROXIMEL FUMARATE, INTERFERON BETA-1A, INTERFERON BETA-1A, GLATIRAMER ACETATE, Betaferon 250 microgram/ml, powder and solvent for solution for injection, OFATUMUMAB, GLATIRAMER ACETATE, DIMETHYL FUMARATE, PEGINTERFERON BETA-1A, DIMETHYL FUMARATE for relapsing multiple sclerosis (RMS) is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- relapsing multiple sclerosis (RMS)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active